Investment Rating - The report maintains an "Outperform" rating for Li Auto, indicating an expected relative performance above the market benchmark over the next 12-18 months [10][19]. Core Insights - Li Auto's revenue for 2024 is projected at RMB 144.5 billion, reflecting a year-on-year increase of 17%. The fourth quarter of 2024 saw revenue of RMB 44.3 billion, up 6% year-on-year and 3% quarter-on-quarter [3][10]. - The net profit attributable to shareholders for 2024 is expected to be RMB 8 billion, down 31% year-on-year, with Q4 2024 net profit at RMB 3.5 billion, down 38% year-on-year but up 25% quarter-on-quarter [3][10]. - For Q1 2025, vehicle deliveries are anticipated to be between 88,000 and 93,000 units, representing a year-on-year increase of 9.5% to 15.7%. Total revenue for this period is expected to be between RMB 23.4 billion and RMB 24.7 billion, down 8.7% to 3.5% year-on-year [3][10]. Financial Data Summary - Key financial metrics for Li Auto from 2023 to 2027 are as follows: - Revenue (in million RMB): 2023: 123,851; 2024: 144,460; 2025E: 189,483; 2026E: 210,516; 2027E: 230,781, with year-on-year growth rates of 173.5%, 16.6%, 31.2%, 11.1%, and 9.6% respectively [2][3]. - Net Profit (in million RMB): 2023: 11,704; 2024: 8,032; 2025E: 13,146; 2026E: 15,434; 2027E: 17,955, with year-on-year growth rates of 681.7%, -31.4%, 63.7%, 16.6%, and 15.9% respectively [2][3]. - Fully Diluted EPS (in RMB): 2023: 5.52; 2024: 3.79; 2025E: 6.19; 2026E: 7.27; 2027E: 8.46 [2][3]. Market Position and Strategy - Li Auto is focusing on enhancing user experience through intensive OTA upgrades, which have led to an increase in the order proportion of the ADMax version, particularly in models priced above RMB 300,000 [3][10]. - The company is set to launch its first pure electric SUV, the Li Auto i8, in July 2025, as part of its dual-energy strategy, while also expanding its charging network with 1,874 supercharging stations and 10,008 charging poles by February 2025 [3][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Views - The company is expected to see steady growth in HNB (Heated Not Burned) products in 2025, with significant contributions anticipated in the second half of the year. The potential of the aerosol medical business is also highlighted as a key component of the company's 2030 goals [11] - Revenue for 2024 is projected at 117.99 billion CNY, with a year-on-year growth of 5.3%, while net profit is expected to decline by 20.8% to 13.03 billion CNY [1][11] - The company is focusing on expanding its HNB and aerosol medical product lines, with R&D investments showing significant increases in these areas [3][11] Financial Performance - In 2024, the company achieved a revenue of 117.99 billion CNY, with a net profit of 13.03 billion CNY, resulting in a net profit margin of 11.05% [1] - The company’s revenue for the fourth quarter of 2024 was 34.63 billion CNY, reflecting an 8% increase year-on-year, but a decline in profit by 42% due to high expenses [1] - The projected revenues for 2025, 2026, and 2027 are 128.92 billion CNY, 151.12 billion CNY, and 173.48 billion CNY, respectively, with corresponding net profits of 16.19 billion CNY, 21.21 billion CNY, and 26.59 billion CNY [11][12] Market Potential - The global market for electronic aerosol is expected to reach 91.42 billion USD by 2029, with a CAGR of approximately 7.4% from 2024 to 2029 [4] - The heated not burned market is projected to reach 66.86 billion USD by 2029, with a CAGR of about 10.1% during the same period [4] - The aerosol medical market is anticipated to grow significantly, with the global market for pulmonary drugs and delivery devices expected to reach 93.28 billion USD by 2030 [4]

Investment Rating - The report maintains a "Buy" rating for the company [1][5] Core Views - The company achieved a significant improvement in profitability in 2024, with total revenue reaching USD 10.259 billion, a year-on-year increase of 15.9%, driven by strong global parcel volume growth [8] - Adjusted EBITDA rose to USD 778 million, reflecting a substantial increase of 430.5%, indicating enhanced profitability [8] - The company turned a profit with a net income of USD 114 million in 2024, compared to a loss of USD 1.156 billion in 2023 [8] - The report highlights the continued improvement in domestic business profitability and the ongoing increase in overseas market share [5] Financial Performance Summary - The company’s revenue for 2024 was USD 10.259 billion, with a growth rate of 15.9% [7] - Adjusted EBITDA for 2024 was USD 778 million, showing a significant increase of 430.5% [8] - The net profit for 2024 was USD 114 million, a turnaround from a loss of USD 1.156 billion in 2023 [8] - The operating cash flow for 2024 reached USD 807 million, a year-on-year increase of 136.1% [8] Parcel Volume and Cost Control - The global parcel volume reached 24.65 billion pieces in 2024, a year-on-year increase of 31.0% [8] - The cost per parcel in Southeast Asia decreased from USD 0.67 to USD 0.57, and in China from USD 0.34 to USD 0.30, demonstrating effective cost control [8] - Despite a slight decline in revenue per parcel due to competitive pricing adjustments, overall profitability improved due to cost reductions [8] Regional Performance - Southeast Asia remains the core market with a parcel volume of 4.56 billion pieces and a market share of 28.6% [8] - In China, the parcel volume reached 19.8 billion pieces, with a market share of 11.3%, ranking sixth in the industry [8] - New markets, including the Middle East and South America, saw revenue growth of 76.1% to USD 576 million, indicating successful market expansion efforts [8]

港股公司报告 | 公司点评 华润建材科技（01313） 证券研究报告 优质资产或被显著低估，维持"买入"评级 25 年水泥涨价盈利弹性可期，优质资产或被显著低估 公司 24 年全年实现归母净利润 2.11 亿元，同比下降 67.25% 公司发布 24 年年报，全年实现收入/归母净利润 230.38/2.11 亿元，同比 -10.47%/-67.25%，实现扣非归母净利润 2.11 亿元，同比-36.73%。其中 Q4 单季度实现收入 70.4 亿元，同比-16.4%，归母净利润-0.98 亿元，同比增 亏，扣非归母净利润-0.98 亿元，同比减亏。24 年公司共计提减值 5 亿元， 其中商誉/固定资产/存货减值分别计提 2.68/1.59/0.66 亿元。 水泥主业量价有所下滑，25 年水泥涨价盈利弹性可期 24 年公司水泥熟料收入 1.5 亿元，同比下降 20%，销量同比-11%达 6171 万吨，测算吨均价同比下滑 29 元（-11%）达 244 元，吨成本同比下降 33 元（-14%）达 207 元，主要受煤炭采购价格同比降低 14%影响，吨毛利同 比提升 4 元（+13%）达 37 元。Q4 水泥价格 ...

Investment Rating - The report assigns a "Neutral" rating with a total score of 69 out of 100 [3][14]. Core Insights - The company has a promising pipeline with products that, if approved, could meet significant demand in the Chinese market, particularly for conditions like Pediatric Growth Hormone Deficiency (PGHD) and Hypoparathyroidism [2][8][10]. - The company is positioned as the first endocrine drug manufacturer in the Hong Kong market, which may provide a competitive edge [14]. Industry Outlook - PGHD is prevalent among children under 18, accounting for 41.5% of short stature cases in China, with only 5.3% treatment rate in 2023, indicating a substantial unmet need [2]. - The market for achondroplasia treatment is currently limited, with only two products in clinical trials, suggesting a strong first-mover advantage for the company's product, Navepegritide [6]. - The demand for drugs treating Hypoparathyroidism is expected to grow, with the patient population projected to increase from 410,100 in 2023 to 495,600 by 2030 [7]. Company Operations - The company has not yet launched any products, resulting in no sales revenue. The net loss for shareholders in 2023 was approximately 250 million RMB, a 13.5% reduction year-on-year [8]. - Research and development costs have decreased significantly, contributing to the reduced net loss, while cash flow from operating activities remains healthy with no bank loans [8]. - The company has a robust pipeline with core products already approved in Europe and the U.S., with expectations for approval in China by 2025 [5][10]. Valuation Level - The company's valuation is considered reasonable, with a market capitalization range of 77.0 to 84.6 billion HKD, slightly lower than comparable companies in the biotech sector [10][12]. - The price-to-book ratio for the company's IPO price is estimated at 18.3 to 20.2 times, which is competitive compared to peers [10]. Market Sentiment - The recent market atmosphere has improved, with a higher percentage of newly listed companies experiencing price increases on their debut [13]. - The presence of notable cornerstone investors, such as WuXi Biologics, indicates confidence in the company's research capabilities [14].

Investment Rating - The report maintains a "Buy" rating for the company [1][5] Core Views - The company achieved a significant improvement in profitability in 2024, with total revenue reaching USD 10.259 billion, a year-on-year increase of 15.9%, driven by strong global parcel volume growth [8] - Adjusted EBITDA rose to USD 778 million, reflecting a substantial increase of 430.5%, indicating enhanced profitability [8] - The company turned a profit with a net income of USD 114 million in 2024, compared to a loss of USD 1.156 billion in 2023 [8] - The report highlights the continued improvement in domestic business profitability and the ongoing increase in overseas market share [5] Financial Performance Summary - The company’s revenue is projected to grow from RMB 63.056 billion in 2023 to RMB 109.376 billion by 2027, with a compound annual growth rate (CAGR) of approximately 13% [7] - The adjusted EBITDA is expected to improve significantly from a loss of RMB 4.107 billion in 2023 to a profit of RMB 11.567 billion by 2027 [7] - The net profit is forecasted to increase from a loss of RMB 7.845 billion in 2023 to RMB 6.341 billion by 2027, representing a growth rate of 240.1% in 2025 [7] - Earnings per share (EPS) are expected to rise from a loss of RMB 0.88 in 2023 to RMB 0.71 by 2027 [7] Market and Operational Insights - The company’s global parcel volume reached 24.65 billion pieces in 2024, marking a year-on-year growth of 31.0% [8] - The Southeast Asia market remains a core area, with parcel volume reaching 4.56 billion pieces and a market share increase to 28.6% [8] - In China, parcel volume reached 19.8 billion pieces, with a market share of 11.3%, ranking sixth in the industry [8] - The company has made strategic price adjustments to expand its market share in Southeast Asia, which has slightly impacted single-ticket revenue but has improved cost efficiency [8]

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 82.62 HKD based on a 2025 PE of 25X [2][9]. Core Insights - Miu Miu's retail revenue grew by 93% in 2024, with EBIT margin reaching a 10-year high. Overall revenue increased by 14.9% YoY to 5.43 billion Euros, while net profit rose by 25% YoY to 839 million Euros [2][9]. - The company is expected to continue its strong growth trajectory, with net profit forecasts of 972 million Euros, 1.088 billion Euros, and 1.191 billion Euros for 2025-2027, representing growth rates of 15.9%, 11.9%, and 9.5% respectively [2][9]. Financial Data and Forecasts - Key financial metrics for the company include: - Revenue (million Euros): 2023: 4726, 2024: 5432, 2025E: 6059, 2026E: 6646, 2027E: 7207 [2][6]. - Net Profit (million Euros): 2023: 671, 2024: 839, 2025E: 972, 2026E: 1088, 2027E: 1191 [2][6]. - Gross Margin (%): 2024: 79.84%, 2025E: 79.80%, 2026E: 79.90%, 2027E: 80.00% [2][6]. - Return on Equity (%): 2024: 19.07%, 2025E: 19.84%, 2026E: 19.93%, 2027E: 19.63% [2][6]. Retail Performance and Strategy - The retail network optimization is evident, with a slight decrease in the number of direct stores to 609, and a net opening of 3 stores. The company plans to continue retail investments and expand Miu Miu into new markets [2][9]. - Retail revenue growth in 2024 was notable across regions, with Asia-Pacific, Europe, Americas, Japan, and the Middle East showing growth rates of 13%, 18%, 9%, 46%, and 26% YoY respectively [2][9]. Management Changes - Miu Miu appointed Silvia Onofri as the new CEO, who has extensive experience in the luxury sector, previously holding positions at Bulgari and Bally [2][9].

Investment Rating - The investment rating for the company is "Outperform" [5][14]. Core Insights - The report highlights that the company's gross profit margin remains robust at 60.2% for Q4, with expectations for revenue growth to improve in Q1 2025 [7][14]. - The company has announced a buyback plan, reflecting long-term confidence in its performance [2][14]. - The overall revenue for 2024 is projected to decline by 2.5% to USD 3.59 billion, with a slight recovery expected in 2025 [7][14]. Financial Data and Forecasts - **Revenue Forecast**: - 2023: USD 3,682 million - 2024: USD 3,589 million - 2025E: USD 3,743 million - 2026E: USD 3,928 million - 2027E: USD 4,118 million - Year-over-year growth rates show a decline of 2.5% in 2024, followed by modest growth in subsequent years [4][11]. - **Net Profit Forecast**: - 2023: USD 417 million - 2024: USD 346 million - 2025E: USD 382 million - 2026E: USD 413 million - 2027E: USD 440 million - The net profit margin is expected to recover gradually after a decline in 2024 [4][11]. - **Earnings Per Share (EPS)**: - 2023: USD 0.29 - 2024: USD 0.24 - 2025E: USD 0.26 - 2026E: USD 0.28 - 2027E: USD 0.30 [4][11]. - **Gross Margin**: - 2023: 59.3% - 2024: 60.0% - 2025E: 60.0% - 2026E: 60.1% - 2027E: 60.2% [4][11]. - **Return on Equity (ROE)**: - 2023: 28.8% - 2024: 23.4% - 2025E: 20.6% - 2026E: 18.2% - 2027E: 16.2% [4][11]. Market Performance - The company's stock closed at HKD 19.10, with a 52-week price range of HKD 16.78 to HKD 31.60 [5][14]. - The total market capitalization is approximately HKD 27,930 million [5][14]. Revenue Performance by Region - Q4 2024 revenue showed a slight decline of 0.1% year-over-year, with a currency-neutral increase of 1% [7][14]. - Revenue changes in Q4 2024 by region were as follows: - Asia: -6.3% - North America: +3.9% - Europe: +5.6% - Latin America: +14% [7][14]. Cash Flow and Dividends - Adjusted free cash flow increased by 9.3% to USD 310 million [7][14]. - Total dividends for the year were USD 150 million, with a payout ratio of 43.4% [7][14].

Investment Rating - The report maintains an "Outperform" rating for Haitian International [2] Core Views - Haitian International achieved a revenue of RMB 16.13 billion in 2024, representing a year-on-year increase of 23.4%, with a net profit of RMB 3.08 billion, up 23.6% year-on-year [3][11] - The company is focused on enhancing its global market share through multi-dimensional market strategies and active globalization efforts [5][14] - The target price is set at HKD 26.3, with a projected P/E ratio of 12 for 2025 [5][15] Revenue and Profit Growth - The company reported a gross margin of 32.5% for 2024, an increase of 0.4 percentage points from the previous year, driven by lower raw material prices and improved economies of scale [3][11] - In the second half of 2024, revenue reached RMB 8.11 billion, a 21.2% increase year-on-year, with net profit attributable to shareholders of RMB 1.56 billion, up 26.4% year-on-year [3][11] Regional Performance - Domestic revenue for 2024 was RMB 10.11 billion, a 27.7% increase year-on-year, while overseas revenue was RMB 6.02 billion, up 16.8% year-on-year [4][12] - The company experienced significant growth in the Mars and Zhafir series of injection molding machines, benefiting from demand recovery in consumer goods and home appliances [4][13] Future Outlook - The company plans to continue benefiting from the recovery of global manufacturing and domestic consumption demand, aiming to expand into both mature and emerging markets [5][14] - Factories in Japan and Serbia are expected to be completed in 2025, enhancing the localization of the supply chain [5][14] Earnings Forecast and Valuation - The revenue forecast for 2025 is RMB 17.1 billion, with a net profit of RMB 3.24 billion, and for 2026, revenue is projected at RMB 15.8 billion with a net profit of RMB 2.88 billion [5][15]

Investment Rating - The report maintains a "Buy" rating for China Tower (0788.HK) [3]. Core Views - The company's performance is driven by its "One Body, Two Wings" strategy, leading to steady growth and an increased focus on shareholder returns through a higher dividend payout ratio [1]. - In 2024, the company reported a revenue of RMB 97.772 billion, a year-on-year increase of 4.0%, with a net profit of RMB 10.729 billion, reflecting a 10% growth [1]. - The EBITDA for 2024 reached RMB 66.559 billion, up 4.7%, with an EBITDA margin of 68.1% [1]. Summary by Sections Revenue and Profitability - The operator business generated revenue of RMB 84.119 billion, growing by 2.4%, while the two wings business saw revenue of RMB 13.388 billion, up 16.4% [1]. - The company achieved a significant improvement in cash flow, with operating cash flow of RMB 49.468 billion, a year-on-year increase of RMB 16.628 billion [1]. Operator Business - The tower business revenue was RMB 75.689 billion, a 0.9% increase, with the number of tower sites increasing to 2.094 million [1]. - The indoor distribution business revenue reached RMB 8.430 billion, growing by 18.1%, with significant expansions in coverage areas [1]. Two Wings Business - The smart connection business generated RMB 8.911 billion, a 22.4% increase, focusing on sectors like emergency services and agriculture [1]. - The energy business revenue was RMB 4.477 billion, up 6.2%, while the battery swap business revenue reached RMB 2.5 billion, growing by 20.9% [1]. Shareholder Returns - The company increased its dividend payout ratio, distributing a total dividend of RMB 0.41696 per share for 2024, an 11.5% increase from 2023 [1]. - The depreciation and amortization as a percentage of revenue decreased from 52.2% in 2023 to 51.4% in 2024, indicating effective investment management [1]. Profit Forecast and Valuation - The net profit forecast for 2025 and 2026 has been adjusted downwards by 10% and 14% to RMB 11.726 billion and RMB 18.123 billion, respectively, with a new forecast for 2027 at RMB 19.2 billion [1]. - The report emphasizes the potential for significant profit growth in 2026 due to the expiration of certain tower depreciations [1].